Immutep (NASDAQ:IMMP) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Immutep (NASDAQ:IMMP) from a hold rating to a sell rating in a research note published on Saturday.

Immutep Price Performance

Immutep stock opened at $1.74 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.25 and a current ratio of 18.25. The firm has a 50-day moving average of $1.78 and a 200-day moving average of $1.89. Immutep has a one year low of $1.32 and a one year high of $2.80.

Institutional Trading of Immutep

Institutional investors have recently bought and sold shares of the business. OLD Mission Capital LLC acquired a new position in Immutep during the fourth quarter worth about $36,000. Two Sigma Securities LLC bought a new position in shares of Immutep in the 4th quarter worth $74,000. Jane Street Group LLC raised its stake in shares of Immutep by 14.7% in the first quarter. Jane Street Group LLC now owns 51,574 shares of the biotechnology company’s stock worth $91,000 after purchasing an additional 6,617 shares during the last quarter. Finally, ABC Arbitrage SA bought a new position in shares of Immutep in the fourth quarter valued at approximately $152,000. Institutional investors own 2.32% of the company’s stock.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.